Astellas Submits Fezolinetant New Drug Application to U.S. FDA ...Middle East

PR Newswire - News
Astellas Submits Fezolinetant New Drug Application to U.S. FDA
Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause TOKYO, June 23, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced a New Drug Application (NDA) for fezolinetant...

Hence then, the article about astellas submits fezolinetant new drug application to u s fda was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas Submits Fezolinetant New Drug Application to U.S. FDA )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News